Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant *Mycobacterium tuberculosis* from Henan Province

**Jie Shi**
Ruyue Su
Danwei Zheng
Yankun Zhu
Xiaoguang Ma
Shaohua Wang
Hui Li
Dingyong Sun

Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan Province, People’s Republic of China

**Purpose:** This study was designed to identify the phenotypic and genotypic characteristics of pyrazinamide (PZA) resistance among multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB) from Henan and to evaluate the efficacy of *pncA*, *rpsA*, and *panD* mutations in predicting PZA resistance.

**Materials and Methods:** A total of 152 MDR strains were included in this study. The Bactec MGIT system was used to determine PZA susceptibility for all strains. The *pncA*, *rpsA*, and *panD* genes were sequenced to identify any mutations, and the sequences were then aligned with the sequence of standard strain H37Rv. Moreover, the correlations between PZA-resistant phenotypes and treatment outcomes were analysed.

**Results:** Of the 152 strains, 105 had a PZA-resistant phenotype, and 102 harboured the *pncA* mutation. The PZA resistance rate was higher in the strains with resistance to all four first-line drugs and those that were pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR). A total of 100 different *pncA* mutation patterns were identified, including 80 point mutations and 20 insertions/deletions, and 32 new *pncA* mutation patterns were detected. In this study, 13 strains had multiple mutations. Of the 11 PZA-resistant strains without *pncA* mutations, two harboured the *rpsA* mutation, and one harboured the *panD* mutation. With PZA susceptibility results as the reference, single-gene *pncA* sequencing had sensitivity of 89.52% and specificity of 89.36%. With the combination of *rpsA* and *panD*, the sensitivity increased to 92.38%, and the specificity remained the same. No significant differences were observed in the sputum smear/culture conversion rate between PZA-resistant patients and PZA-sensitive patients. However, PZA resistance was related to the time to sputum smear/culture conversion (*P* = 0.018).

**Conclusion:** The combination of *pncA*, *rpsA*, and *panD* was beneficial for the timely diagnosis of PZA resistance and could provide a laboratory basis for customizing treatment regimens for MDR-TB patients.

**Keywords:** *Mycobacterium tuberculosis*, multidrug-resistant, pyrazinamide, *pncA*, *rpsA*, *panD*

**Introduction**

Multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB, resistant to at least two of the most powerful first-line anti-TB drugs, isoniazid and rifampin) remains a critical global public health problem due to its high treatment failure rate.1–3 According to the latest 2019 report from the World Health Organization (WHO), there were approximately 10 million new cases of TB worldwide, and approximately 1.2 million HIV-negative patients died of tuberculosis. China has the second highest MDR-TB burden,
after only India, with approximately 120,000 cases of MDR-TB per year. A national survey of drug-resistant tuberculosis in China showed that the incidence of TB is 5.7%, and 25.6% of retreated patients were infected with MDR-TB, significantly higher than global average level. The large number of patients with MDR-TB hinders the effective prevention and control of TB in China.

Pyrazinamide (PZA) is an important first-line anti-TB drug, with effective bactericidal activity against both drug-sensitive and MDR strains. As a prodrug, PZA is converted by pncA-encoded pyrazinamidase (PZase) into pyrazinoic acid (POA) to exhibit bactericidal activities. The accumulation of POA in cells results in cytoplasmic acidification, which depletes cellular membrane potentials, inhibits various intracellular targets, and eventually leads to cell death. PZA is effective against persistent bacteria in macrophages, which cannot be killed by other anti-TB drugs. Due to its unique antibacterial activity, PZA reduces the treatment time from 12months to 6months when it is combined with isoniazid and rifampicin. Studies have shown that 72.98% of PZA resistance is due to pncA mutations, which are highly diverse and scattered in open reading frames and upstream regulatory regions. In addition to pncA mutations, other mechanisms can cause PZA resistance. For example, mutations in rpsA, which encodes 30S ribosomal S1 proteins, can alter the POA binding site, causing PZA resistance. Some studies have shown that panD is associated with PZA resistance. Researchers are still debating the role of rpsA and panD mutations in PZA resistance, and more experimental data are needed to clarify the contributions of rpsA and panD to PZA resistance.

PZA has antibacterial activity only at a low pH; thus, an acidic environment is needed for PZA susceptibility tests. Due to the complex procedures and the failure probability of PZA susceptibility tests, only a few laboratories perform these experiments. However, previous studies have shown that approximately 16% of TB patients are PZA resistant. Specifically, the PZA resistance rate is 2–7.5% in non-MDR-TB patients and 36–85% in MDR-TB patients. Therefore, the reliable prediction of PZA resistance before treatment facilitates the development of more effective treatments. As the most populous region in China, Henan has the largest number of patients with TB and MDR-TB in the country, making it a hotspot for TB prevention. While PZA is widely used to treat MDR-TB patients, few studies have been conducted to investigate the prevalence of PZA resistance in MDR strains in Henan. In this study, we investigated PZA resistance in MDR-TB patients in Henan and analysed the mutation patterns of PZA resistance-related genes. Moreover, we observed the correlations between PZA resistance and treatment outcomes.

Materials and Methods

Sample Source

MDR-TB patients from 10 regions of Henan during 2018 were included in this study. The patients were followed up for 2 years, with monthly sputum smears and Mycobacterium tuberculosis cultures during treatment. The study was approved by the Medical Ethics Committee of Henan Provincial Center for Disease Control and Prevention (Number: 2014-KY-012-01). All patients provided informed consent, and this study was conducted in accordance with the Declaration of Helsinki. We collected patient information from medical records. Retreated patients were defined as those receiving more than 1 month of irregular chemotherapy for tuberculosis before presenting at our hospitals.

Drug Susceptibility Testing (DST)

Drug susceptibility testing was performed with WHO-recommended proportion method. The drug concentrations in Lowenstein-Jensen medium were 0.2 μg/ml isoniazid (INH), 40 μg/ml rifampicin (RIF), 4 μg/ml streptomycin (SM), 2 μg/ml ethambutol (EMB), 30 μg/ml kanamycin (KAM), 30 μg/ml amikacin (AMK), 2 μg/ml levofloxacin (OFLX), 1 μg/ml p-aminosalicylic acid (PAS), 40 μg/ml capreomycin (CAM), and 40 μg/ml prothionamide (PTO). Resistant strains were considered when more colonies (>1%) were growing on the drug-containing medium than on the control medium. Bactec MGIT 960 was used for the PZA susceptibility test, and the concentration of PZA in the liquid medium was 100μg/mL. For strains with inconsistent results between DST and DNA sequencing, the tests were repeated, and the minimum inhibitory concentration (MIC) in liquid 7H9 medium was measured. Strains resistant to both isoniazid and rifampicin were defined as MDR strains. In addition to MDR, strains resistant to levofloxacin and at least one second-line injectable anti-tuberculosis drug (amikacin, capreomycin, or kanamycin) were considered extensively drug-resistant (XDR) strains.

DNA Extraction and PCR (Review 1), Sequencing and Characterization of Mutations in pncA, rpsA and panD (Review 2)

Fresh cultured bacteria on Lowenstein-Jensen medium were scraped into 500 μL of Tris-EDTA (TE) buffer,
inactivated at 85°C for 30 min, boiled for 5 min, and then centrifuged for later use.\textsuperscript{17} Crude DNA extract was used as the template for polymerase chain reaction (PCR). The primers were as follows: \textit{pncA}-5′-AACAGTTTATC CGGGTTTC and \textit{pncA}-3′-CCGTCATGGCCCTATATC; \textit{rpsA}-5′-CGGACACCCCAACAATA and \textit{rpsA}-3′-GTGG ACAGCAACGACTTC; and \textit{panD}-5′-TCAACGGTTCC CGTCGGCTGCT and \textit{panD}-3′-TATCCGCCACTGCTGC ACGACCTT. The 20μL PCR mixture was prepared as follows: 10 μl of 2 × GoldStar MasterMix (CWBO Biotech Company, China), 5 μL of DNA template, and 0.2 μM of each primer set. The PCR conditions for amplification were 5 min at 94°C, followed by 35 cycles of 94°C for 1 min, 59°C for 1 min, 72°C for 1 min, and a final extension of 72°C for 10 min. The PCR products were sent to Shanghai Sangon Biotech Company for sequencing. All of the sequence results were aligned with the \textit{pncA}, \textit{rpsA}, and \textit{panD} genes from reference strain H37Rv (GenBank accession no. NC000962) using DAMAN(version6.0) software.

**Genotyping**

Spoligotyping analysis was performed in accordance with the previous literature.\textsuperscript{18} Briefly, the primers DR3′-CC GAGAGGGACGAAAC and DR5′-GGTTTTGGRCTG TGACGAC were used for PCR of the extracted genome samples, and then the PCR products were hybridized with a membrane precoated with 43 spacer oligonucleotides to determine the results. The spoligotyping results were aligned through the SITVITWEB website (http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/). The primers NTF-5′-CCAGATATCGGTTGTCGACandNTF-3′-GCCGGT TCTCGAAATCTAAACAA were designed based on the NTF (nuclear transcription factor) region of \textit{M. tuberculosis}.

The strain was defined as “modern-type” in the presence of the IS6110 insertion or “ancient type” in the absence of the IS6110 insertion according to a previous report.\textsuperscript{20}

**Data Analysis**

SPSS software, version 19.0, was used for data analysis, and the chi-square test was performed to analyse the correlations between categorical variables. \(P<0.05\) was considered statistically significant.

**Results**

**PZA Susceptibility Testing and Patients Demographics**

In this study, a total of 152 MDR-TB strains were included, and 105 (69.02%) were resistant to PZA. Moreover, 43 of the 152 strains (28.29%) were pre-extensively drug resistant (pre-XDR), 37 (86.04%) were PZA resistant; and 25 (16.44%) were XDR, 23 (92%) were PZA resistant. In addition, 102 (71.71%) strains were resistant to all four first-line anti-tuberculosis drugs, and 82 (58.09%) were resistant to PZA. These results showed that pre-XDR strains, XDR strains, and strains resistant to all four first-line drugs were more likely to develop PZA resistance.

Of the 152 MDR strains, 119 (78.28%) were resistant to streptomycin, 85 (55.92%) were resistant to ethambutol, 35 (23.02%) were resistant to kanamycin, 63 (41.44%) were resistant to levofloxacin, 35 (23.02%) were resistant to amikacin, 25 (16.45%) were resistant to capreomycin, 23 (15.13%) were resistant to prothionamide, and 15 (9.86%) were resistant to p-aminosalicylic acid (Table 1). MDR strains that were resistant to ethambutol, streptomycin, and levofloxacin were more likely to develop PZA resistance.

We further analysed the correlation between PZA resistance and clinical information, including sex, age, close contact history with tuberculosis patients, previous treatment, and tuberculosis genotype. The results showed that the PZA resistance rate was significantly higher among men than women (odds ratio (OR): 2.64, 95% confidence interval (CI): 1.29–5.40, \(P=0.009\)), and the percentage of retreated MDR-TB patients in the PZA-resistant group was significantly higher than in the PZA-susceptible group (OR: 4.07,95 CI: 1.92–8.83, \(P<0.001\)). Analysis of the correlations between the genotypes of these strains and PZA resistance showed that the Beijing family had a higher frequency of PZA resistance than other genotypes and that modern-type strains were more likely to develop PZA resistance than ancient type strains.

**Mutations in MDR Strains**

The \textit{pncA} genes of 152 strains were sequenced and analysed, and the data showed that the PZA susceptibility results were consistent with the \textit{pncA} mutation for 133 strains. Eight PZA-susceptible strains harbour\textit{pncA} mutations, including three synonymous mutations. Eleven strains were resistant by the test of MGIT960 but harboured...
Table 1 PZA Resistance in Different Groups of MDR-TB Patients

| Characteristics          | No. of Isolates (n=152) | No. of PZA Resistant Isolates (n=105) | No. of PZA Susceptible Isolates (n=47) | OR       | 95% CI       | P value |
|--------------------------|-------------------------|--------------------------------------|---------------------------------------|----------|--------------|---------|
| Age                      |                         |                                      |                                       |          |              |         |
| <20                      | 28                      | 18                                   | 10                                    | 0.77     | 0.32–1.85    | 0.65    |
| 21–40                    | 39                      | 26                                   | 13                                    | 0.86     | 0.39–1.87    | 0.69    |
| 41–60                    | 61                      | 45                                   | 16                                    | 1.43     | 0.71–2.97    | 0.32    |
| >60                      | 24                      | 16                                   | 8                                     | 0.88     | 0.34–2.22    | 0.81    |
| Sex                      |                         |                                      |                                       |          |              |         |
| Female                   | 51                      | 28                                   | 23                                    | 1.00     | (reference)  |         |
| Male                     | 101                     | 77                                   | 24                                    | 2.64     | 1.29–5.40    | <0.001  |
| Treatment History        |                         |                                      |                                       |          |              |         |
| New case                 | 43                      | 20                                   | 23                                    | 1.00     | (reference)  |         |
| Retreated                | 109                     | 85                                   | 24                                    | 4.07     | 1.92–8.63    | <0.001  |
| Drug resistance to       |                         |                                      |                                       |          |              |         |
| Ethambutol               | 85                      | 66                                   | 0                                     | 2.45     | 1.23–5.04    | 0.01    |
| Streptomycin             | 119                     | 90                                   | 19                                    | 3.724    | 1.67–8.31    | <0.001  |
| Kanamycin                | 35                      | 25                                   | 10                                    | 1.156    | 0.50–2.65    | 0.84    |
| Levofloxacin             | 63                      | 53                                   | 10                                    | 2.39     | 1.17–4.89    | 0.02    |
| Capreomycin              | 25                      | 17                                   | 8                                     | 0.942    | 0.37–2.37    | 1       |
| P-aminsalicilic acid     | 15                      | 13                                   | 2                                     | 3.179    | 0.69–14.70   | 0.15    |
| Protonamide              | 23                      | 16                                   | 7                                     | 1.027    | 0.39–2.69    | 1       |
| Amikacin                 | 35                      | 23                                   | 12                                    | 0.82     | 0.37–1.83    | 0.68    |
| All four first-line drug resistant | 109                 | 82                                   | 27                                    | 2.64     | 1.26–5.54    | 0.01    |
| Pre-extensive-drug resistant | 53                 | 43                                   | 10                                    | 2.57     | 1.15–5.71    | 0.02    |
| Extensive-drug resistant | 27                      | 25                                   | 2                                     | 7.03     | 1.59–31.07   | <0.001  |
| Spoligotyping            |                         |                                      |                                       |          |              |         |
| Beijing family           | 127                     | 97                                   | 30                                    | 6.87     | 2.70–17.50   | <0.001  |
| T family                 | 10                      | 6                                    | 4                                     | 0.652    | 1.07–2.42    | 0.49    |
| Other family             | 14                      | 2 d                                  | 12 e                                  | 0.057    | 0.01–0.27    | <0.001  |
| NTF type                 |                         |                                      |                                       |          |              |         |
| Ancestral type           | 34                      | 12                                   | 22                                    | 1.00     | (reference)  |         |
| Modern type              | 118                     | 93                                   | 25                                    | 6.82     | 2.97–15.45   | <0.001  |

Notes: 1 Pre-XDR strains: MDR strains that were also resistant to levofloxacin or any injectable drug (kanamycin, capreomycin, amikacin). 2 XDR strains: MDR strains that were also resistant to levofloxacin and any injectable drug (kanamycin, capreomycin, amikacin). 3 Including the T1, T2, and T3 genotypes. 4 Two strains in the MNU2 family. 5 Seven strains in the MNU2 family, four in the H3 family, and one with an unknown genotype.

no pncA mutations. As a result, with PZA susceptibility phenotype as the gold standard, pncA mutation detection showed sensitivity of 89.52% (95% CI, 81.64–94.39%) and specificity of 89.36% (95% CI, 76.10–96.01%) in predicting PZA resistance.

Of the 152 MDR strains, 50 harboured no mutations, and 102 harboured pncA mutations, of which 82 strains had base mutations (including three nonsense mutations and three synonymous mutations), and 20 had frame shift mutations. Moreover, 13 strains harboured multiple mutations, including double mutations in eight strains, triple mutations in three strains, and four mutations in two strains. The remaining 89 strains harboured a single pncA mutation, either a single base mutation or a synonymous mutation (Table 2).

Different mutation patterns were detected in these resistant strains, including 14 insertions, 6 deletions, and 80 point mutations. These mutations were scattered
throughout the entire length of the *pncA* gene, including the promoter region. Seven strains harboured a mutation in the promoter region of *pncA*, including an insertion of GAT locus −7 for one strain, a T to C nucleotide substitution at locus −11 for five strains, and an A to G transition at locus −12 for one strain. For the remaining 95 strains, *pncA* mutations were found in the open reading frame. Three strains harboured a large segment deletion, including deletions of codons 79 to 92, codons 189 to 218, and codons 196 to 221. In this study, we detected 32 new mutations that were not found in the GMTV and TBDReA MDB databases or reported in previous studies, including 16 substitution mutations and 16 frame shift mutations (Table 3).

The mutations of *pncA* in MDR strains from Henan were diverse. The PZA-resistant strains harboured 100 different mutant types, nine of which were found in multiple strains (Table 3). Specifically, codon 359 was associated with the highest mutation rate, and its mutation (Leu to Arg) was found in eight strains (12.3%). Locus-11 of the *pncA* promoter was associated with the second highest mutation rate; this mutation was found in five strains. Codon 226 mutations (Thr to Pro) were found in four strains (6.8%). In addition, six mutant types were found in two drug-resistant strains.

Eight PZA-susceptible strains harboured *pncA* mutations, including three synonymous mutations. It should be noted that A to T substitution at codon 535 was found in both PZA-resistant and PZA-sensitive strains. PZA susceptibility tests and *pncA* sequencing were repeated for these strains, and the results remained the same. The MICs of PZA were determined with 7H9 liquid medium (pH 5.5) for these eight strains. The results showed that the MIC was 12.5 μg/mL for three strains with a synonymous mutation, 25 μg/mL for two strains, and 50 μg/mL for three strains, which included the strain with a codon535 mutation (Table 4).

Strains without *pncA* mutations could have other mechanisms for PZA resistance. Therefore, other genes associated with PZA resistance were sequenced, including *rpsA* and *panD* (Table 5). No mutations were detected in the promoter regions of *rpsA* and *panD*, and most PZA-resistant strains harbour in *grpsA* or *panD* mutations were also accompanied by *pncA* mutations. In this study, 72.4% (76/105) of PZA-resistant and 74.5% (35/47) PZA-susceptible clinical strains had eight and one point mutations within their *rpsA* genes, separately. *RpsA* mutations were scattered, although most mutations were located in the 180 amino acids of the N-terminus and C-terminus. Notably, no *pncA* mutations were detected in PZA-resistant strains harbouring *rpsA* codon357 and codon532 mutations. The CGA to CGC synonymous mutation in *rpsA* codon 212 is a non-specific mutation that occurred in both the 68PZA-resistant strains and the 35PZA-susceptible strains. Spoligotyping analysis showed that 96 (93.2%) of the 103 strains with a synonymous *rpsA* mutation belonged to the Beijing family and that two strains belonged to the T family. The *rpsA* nonsynonymous mutation frequencies among PZA-resistant XDR strains and MDR strains were 8% (2/25) and 5.5% (6/109), respectively. The XDR strains had a greater tendency to harbour *rpsA* mutations than the MDR strains. No *panD* mutations were detected in the 47PZA-susceptible strains. Two of the 105PZAdrug-resistant strains harboured *panD* mutations, and one of these strains harboured no *pncA* mutations.

To evaluate the efficiency of DNA sequencing for PZA resistance, we compared the sequencing results and the resistance phenotype (Table 6). With the resistance phenotype as a reference, detection of mutations in *pncA* alone showed sensitivity of 89.52% (95% CI, 81.64–94.39%) and specificity of 89.36% (95% CI, 76.10–96.01%); the kappa was 0.76 between the *pncA* mutation and PZA resistance. The concordance between sequencing of *rpsA/panD* and PZA resistance was low, indicating a low diagnostic value for PZA resistance on its own. However, the combination of *rpsA* and *panD* mutations with *pncA* sequencing increased the sensitivity for PZA resistance from 89.52% (95% CI, 81.64–94.39%) to 92.38% (95% CI, 85.54–96.65%) and increased the kappa to 0.80.

### Relationship Between Treatment outcome and PZA Susceptibility Phenotype
To investigate the effect of PZA resistance on treatment outcome, we followed up the patients for 24 months to

| Table 2 | Correlation between *pncA* Mutation Patterns and PZAResistance |
|---|---|---|
| No. of PZA Susceptible | No. of PZA Resistant | Total |
| No mutation | 39 | 11 | 50 |
| Single mutation | 5 | 81 | 86 |
| Silent mutation | 3 | 0 | 3 |
| Multiple mutation | 0 | 13 | 13 |
| Total | 47 | 105 | 152 |
Table 3 Mutant Profiles of MDR-TB Isolates Within pncA

| Nucleotide Position | Nucleotide Change | Amino Acid Position | Amino Acid Change | No. of Isolates |
|---------------------|-------------------|---------------------|------------------|----------------|
| 1                   | -12               | Promoter            | –                | 5              |
| 2                   | -11               | Promoter            | –                | 1              |
| 3                   | ATG to ATA        | 1                   | Met to Ile       | 1              |
| 4                   | TTG to TCG        | 4                   | Leu to Ser       | 1              |
| 5                   | ATC to AGC        | 5                   | Ile to Ser       | 1              |
| 6                   | GTC to TTC        | 7                   | Val to Phe       | 2              |
| 7                   | GTC to GGC        | 7                   | Val to Gly       | 1              |
| 8                   | GAC to GAA        | 8                   | Asp to Glu       | 1              |
| 9                   | GAC to GAG        | 8                   | Asp to Glu       | 1              |
| 10                  | GTG to GCG        | 9                   | Val to Ala       | 2              |
| 11                  | GTG to GGG        | 9                   | Val to Gly       | 1              |
| 12                  | CAG to TAG        | 10                  | Gln to Ala       | 1              |
| 13                  | CAG to CCG        | 10                  | Gln to Pro       | 1              |
| 14                  | GAC to GGC        | 12                  | Asp to Ala       | 2              |
| 15                  | GAC to GGC        | 12                  | Asp to Gly       | 1              |
| 16                  | TTC to GTC        | 13                  | Phe to Val       | 1              |
| 17                  | TGC to GGC        | 14                  | Cys to Gly       | 1              |
| 18                  | TGC to CGC        | 14                  | Cys to Arg       | 1              |
| 19                  | TGC to TAC        | 14                  | Cys to Tyr       | 1              |
| 20                  | GGC to GAC        | 17                  | Gly to Asp       | 1              |
| 21                  | CTG to CCG        | 19                  | Leu to Pro       | 1              |
| 22                  | GTA to GGA        | 21                  | Val to Gly       | 3              |
| 23                  | GGC to GAC        | 24                  | Gly to Asp       | 1              |
| 24                  | GCC to GGG        | 26                  | Ala to Gly       | 1              |
| 25                  | GCC to GAC        | 28                  | Ala to Asp       | 1              |
| 26                  | TTC to GTC        | 32                  | Phe to Val       | 1              |
| 27                  | CTG to CCG        | 35                  | Leu to Pro       | 1              |
| 28                  | CTG to CTC        | 35                  | Leu to Pro       | 1              |
| 29                  | TAC to TAG        | 41                  | Tyr to Stop      | 1              |
| 30                  | CAC to CCC        | 43                  | His to Pro       | 1              |
| 31                  | GCA to CCA        | 46                  | Ala to Pro       | 1              |
| 32                  | GAC to AAC        | 49                  | Asp to Asn       | 1              |
| 33                  | GAC to GGC        | 49                  | Asp to Gly       | 1              |
| 34                  | GAC to GCC        | 49                  | Asp to Ala       | 1              |
| 35                  | CAC to CGC        | 51                  | His to Arg       | 1              |
| 36                  | CCG to TCG        | 54                  | Pro to Ser       | 1              |
| 37                  | CCG to CGG        | 54                  | Pro to Arg       | 1              |
| 38                  | CCG to CAG        | 54                  | Pro to Glu       | 1              |
| 39                  | CAC to CGC        | 57                  | His to Arg       | 1              |
| 40                  | CAC to CAA        | 57                  | His to Gln       | 1              |
| 41                  | TTC to GTC        | 58                  | Phe to Val       | 1              |
| 42                  | CCG to CGG        | 62                  | Pro to Arg       | 1              |
| 43                  | TCC to TGC        | 65                  | Ser to Cys       | 1              |
| 44                  | TCG to CCG        | 66                  | Ser to Pro       | 1              |
| 45                  | TGG to CGG        | 68                  | Trp to Arg       | 1              |
| 46                  | TGG to TCG        | 68                  | Trp to Ser       | 1              |
| 47                  | TGG to TAG        | 68                  | Trp to Stop      | 2              |
| 48                  | CAT to CGT        | 71                  | His to Arg       | 1              |
| 49                  | CAT to CCT        | 71                  | His to Pro       | 1              |

(Continued)
| Nucleotide Position | Nucleotide Change | Amino Acid Position | Amino Acid Change | No. of Isolates |
|---------------------|-------------------|---------------------|-------------------|----------------|
| 50                  | ACT to CCT        | 76                  | Thr to Pro        | 4              |
| 51                  | CTG to CGG        | 85                  | Leu to Arg        | 1              |
| 52                  | ATC to ACC        | 90                  | Ile to Thr        | 1              |
| 53                  | AAG to AGG        | 96                  | Lys to Arg        | 1              |
| 54                  | GGT to GAT        | 97                  | Gly to Asp        | 1              |
| 55                  | CGG to GTG        | 102                 | Ala to Val        | 1              |
| 56                  | TAC to TGC        | 103                 | Tyr to Cys        | 1              |
| 57                  | GCC to GAC        | 105                 | Gly to Asp        | 1              |
| 58                  | TTC to TCC        | 106                 | Phe to Ser        | 1              |
| 59                  | CTG to CGG        | 120                 | Leu to Arg        | 7              |
| 60                  | GTC to GGC        | 125                 | Val to Gly        | 1              |
| 61                  | GTC to GCC        | 125                 | Val to Ala        | 1              |
| 62                  | ATT to ACT        | 133                 | Ile to Thr        | 2              |
| 63                  | GAT to GGT        | 136                 | Asp to Gly        | 1              |
| 64                  | TGT to CTG        | 138                 | Cys to Arg        | 1              |
| 65                  | GTG to GGG        | 139                 | Val to Gly        | 2              |
| 66                  | ACG to CCG        | 142                 | Thr to Pro        | 1              |
| 67                  | ACG to ATG        | 142                 | Thr to Met        | 1              |
| 68                  | GCG to GTG        | 146                 | Ala to Val        | 1              |
| 69                  | GTG to ATG        | 155                 | Val to Met        | 1              |
| 70                  | CTG to TTG        | 154                 | Leu to Leu        | 1              |
| 71                  | CTG to CAG        | 156                 | Leu to Glu        | 1              |
| 72                  | CTG to CCG        | 156                 | Leu to Pro        | 1              |
| 73                  | ACA to CCA        | 160                 | Thr to Pro        | 1              |
| 74                  | GCG to ACG        | 171                 | Ala to Thr        | 1              |
| 75                  | GCG to CCG        | 171                 | Ala to Arg        | 1              |
| 76                  | GAG to GAA        | 173                 | Glu to Glu        | 1              |
| 77                  | AGC to TGC        | 179                 | Ser to Cys        | 2              |
| 78                  | GAG to TAG        | 181                 | Glu to Arg        | 1              |
| 79                  | GAG to GAT        | 181                 | Glu to Arg        | 1              |
| 80                  | AGC to AGT        | 185                 | Ser to Ser        | 1              |
| deletion            |                   |                     |                   |                |
| 81                  | CTGGCCCGCACCAT deletion | 27                | Frameshift        | 1              |
| 82                  | CTATTCTCGTGCGCCACCGCATTCGTCG deletion | 63           | Frameshift        | 1              |
| 83                  | TCGTCGCGCACCGCATTCGTCAG deletion | 64           | Frameshift        | 1              |
| 84                  | C deletion        | 84                  | Frameshift        | 1              |
| 85                  | T deletion        | 141                 | Frameshift        | 1              |
| 86                  | A deletion        | 110                 | Frameshift        | 1              |
| insertion           |                   |                     |                   |                |
| 87                  | G insertion       | promoter             | –                 | 1              |
| 88                  | ACG insertion     | 41                  | Asp insertion     | 1              |
| 89                  | AG insertion      | 44                  | Frameshift        | 1              |
| 90                  | GT insertion      | 67                  | Frameshift        | 1              |
| 91                  | CGGA insertion    | 81                  | Frameshift        | 1              |
| 92                  | C insertion       | 85                  | Frameshift        | 1              |
| 93                  | G insertion       | 86                  | Frameshift        | 1              |

(Continued)
Table 3 (Continued).

| Nucleotide Position | Nucleotide Change | Amino Acid Position | Amino Acid Change | No. of Isolates |
|---------------------|-------------------|---------------------|-------------------|-----------------|
| 94                  | T insertion       | 90                  | Frameshift        | 2               |
| 95                  | G insertion       | 131                 | Frameshift        | 1               |
| 96                  | GG insertion      | 131                 | Frameshift        | 1               |
| 97                  | TG insertion      | 137                 | Frameshift        | 1               |
| 98                  | AG insertion      | 140                 | Frameshift        | 1               |
| 99                  | T insertion       | 150                 | Frameshift        | 1               |
| 100                 | G insertion       | 179                 | Frameshift        | 1               |

Multiple mutations

| 11,178, 535,541 | TTG to TCG, ACA to CCA, AGC to TGC, GAG to TAG | 4,160,179,181 | Leu to Ser, Thr to Pro, Ser to Cys, Glu to Arg | 1 |
| 243, 254, 412  | GAC to GAA, GAC to GCC, CTG to CGG, TGT to CGT | 8,128,138 | Asp to Glu, Asp to Gly, Leu to Arg, Cys to Arg | 1 |
| 105,121, 203   | CTG to CTC, ACG insertion, TGG to TCG | 35,44 | Leu to Pro, Asp insertion, Trp to Ser | 1 |
| 26,40,398      | GTG to GCG, TGC to GGC, ATT to ACT | 9,14,133 | Val to Ala, Cys to Gly, Ile to Thr | 1 |
| 56,145,463     | CTG to CCG, GAC to AAC, GTG to ATG | 19,49,155 | Leu to Pro, Asp to Asn, Val to Met | 1 |
| 19,437         | GTC to TTG, GCG to GTG | 71,46 | Val to Phe, Ala to Val | 1 |
| 77,171         | GCG to GGG,CAC to CAA | 26,57 | Ala to Gly, His to Gln | 1 |
| 40,104         | TGC to CGC, CTG to CCG | 14,35 | Cys to Arg, Cys to Arg | 1 |
| 37,128         | TTC to GTC, CAC to CCC | 13,43 | Phe to Val, His to Pro | 1 |
| 160,253        | CCG to CTG, C insertion | 54,85 | Pro to Ser, Frameshift | 1 |
| 196,212        | TCG to CCG, CAT to CCT | 66,71 | Ser to Pro, His to Pro | 1 |
| 12,29,287      | CAG to CCG, AAG to AGG | 16,10 | Gly to Pro, Lys to Arg | 1 |
| 161,200        | CCG to CCG, C deletion | 54,84 | Pro to Arg, Frameshift | 1 |

Note: *Not found in the TBDRM and GMTV databases or in previous studies.

obtain clinical information. Nine patients failed to provide complete treatment information, including two deaths, two refusals to followup, and five losses. The data showed that after treatment, 93 (93.93%) of the 99 PZA-resistant patients showed sputum smear/culture conversion, while 42 (95.45%) of the 44PZA-susceptible patients showed sputum smear/culture conversion (Table 7). These results indicated no significant difference in sputum conversion rate between PZA-resistant and susceptible patients. However, when the sputum conversion time was segmented and compared with PZA resistance, the results showed that at the end of 6 months of treatment, the sputum smear/
With PZA-resistant culture (78.0%), resistance-related and resistance-related genes. The results showed that 69% (95% CI, 57.8–71.8%) of MDR strains were PZA-resistant, which was similar to that in the Chongqing area (62.4%).

**Discussion**

PZA plays an important role in the treatment of patients with MDR-TB. In this study, we investigated PZA resistance in MDR-TB patients in Henan and analysed the correlations between PZA resistance and mutations in PZA resistance-related genes. The results showed that 46.5% (7.14%) (Table 7), indicating that PZA resistance could affect the time to sputum smear/culture conversion.

**Table 5** Mutant Profiles of rpsA and panD among MDR-TB Isolates

| Nucleotide Position | Nucleotide Change | Amino Acid Position | Amino Acid Change | No. of Isolates | pncA Nucleotide Change(Amino Acid Change) |
|---------------------|-------------------|---------------------|-------------------|-----------------|------------------------------------------|
| **PZA resistant isolates** | | | | | |
| rpsA | 93<sup>a</sup> | AAG to AAC | 31 | Lys to Asn | 2 | T20G (Val7Gly), A212G (His71Pro) |
| | 357<sup>a,b</sup> | CTC to CGC | 119 | Leu to Arg | 1 | wild-type |
| | 368 | GAC to GCC | 123 | Asp to Ala | 1 | C171A(His57Gln) |
| | 532<sup>a,b</sup> | AAG to GAG | 178 | Lys to Glu | 1 | wild-type |
| | 630<sup>a</sup> | ACC to AGC | 210 | Thr to Cys | 1 | G50A(Gly17Asp) |
| | 636<sup>a</sup> | CGA to CGC | 212 | Arg to Arg | 68 | |
| | 949<sup>a</sup> | ATC to GTC | 317 | Ile to Val | 1 | C161G(Pro54Arg) |
| | 1235 | GCC to GTC | 412 | Ala to Val | 1 | G145A(Asp49Asn) |
| panD | 167 | GTC to GCC | 56 | Val to Ala | 1 | T40G(Cys14Gly) |
| | 389<sup>a</sup> | GAG to GGG | 130 | Glu to Gly | 1 | wild-type |
| **PZA susceptible isolates** | | | | | |
| rpsA | 636 | CGA to CGC | 212 | Arg to Arg | 35 | wild-type |

**Notes:** <sup>a</sup>New mutations. <sup>b</sup>No pncA mutations. <sup>c</sup>Also present in PZA-susceptible strains.

**Table 6** Efficacy Evaluation of Sequencing for PZA Resistance in MDR Strains

| gene | PZA Resistant (n=105) | PZA Susceptible (n=47) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | Kappa Coefficient |
|------|----------------------|-----------------------|--------------------------|--------------------------|-----------------|
| pncA | 94 | 11 | 5 | 42 | 89.52 (81.64–94.39) |
| rpsA | 7 | 98 | 0 | 47 | 6.67 (2.94–13.68) |
| panD | 2 | 103 | 0 | 47 | 1.90 (0.23–6.70) |
| pncA/rpsA/panD | 97 | 8 | 5 | 42 | 92.38 (85.54–96.65) |

**Discussion**

In previous reports, the MDR-TB patients who were more likely to develop PZA resistance (78.0% vs 46.5%), suggesting a correlation between a history of tuberculosis and PZA resistance. The higher PZA resistance rate observed in retreated MDR-TB patients could be related to their previous treatment regimens with PZA. As a result, the role of PZA should be carefully considered in the treatment of MDR-TB patients. It was necessary to perform PZA susceptibility tests to develop an optimal treatment regimen for MDR-TB patients.

Previous reports have revealed a correlation between PZA resistance and fluoroquinolone resistance. Similarly, our study showed that PZA resistance was associated with resistance to other anti-tuberculosis drugs,
including EMB, SM and OFLX. When exposed to antibiotics such as rifampicin, fluoroquinolones, and aminoglycosides, bacteria will induce the generation of free oxygen radicals in the body and increase the frequency of gene mutations. Given the prolonged use of antituberculosis drugs by MDR-TB patients, we hypothesized that prolonged drug exposure could induce more genetic mutations in *M. tuberculosis*, eventually leading to cross-resistance to PZA and other drugs.

The genotyping results showed that PZA resistance rates were significantly higher in the Beijing family of *M. tuberculosis* than in the non-Beijing family, and PZA resistance rates were higher in the modern subline ages than in the ancient sub line ages. In this study, approximately 76.3% of Beijing family and 60% of T family strains harboured PZA resistance, the frequency was significantly higher than those among other genotypes (14.3%). However, due to the small sample size, we were unable to reach any definitive conclusions about correlations with *M. tuberculosis* genotypes, whereas previous studies have shown that PZA resistance was not associated with the genotype. 

In this study, the concordance rate was 91.4% between PZA-resistant phenotypes and *pncA* sequences, with discordant results for 13 strains. Eight strains with a *pncA* mutation, including three strains with a synonymous mutation, were susceptible to PZA, while eight strains with wild-type *pncA* were resistant to PZA. To exclude experimental errors, we repeated PZA susceptibility tests for these 13 strains and obtained the same results. The spoligotypes of 16 strains with inconsistent results between resistance and *pncA* gene mutations were analysed, and the results showed that 14 strains belonged to the Beijing genotype and two strains to the T family. We further determined the MICs of PZA-susceptible strains with *pncA* mutations. Except for three strains with a synonymous mutation, the remaining five strains showed low-level PZA resistance (12.5 μg/mL <MIC≤50μg/mL). Drug resistance is the result of the interactions of multiple macromolecules in organisms, including genes, transcripts, and proteins. In addition, some genetic mutations might not necessarily lead to a drug resistance phenotype. 

The *pncA* mutation rate in PZA-resistant strains varies among different regions, eg, 45.7% in Brazil, 34 70.6% in Iran, 35 75.0% in Taiwan, 36 88% in Chongqing, 23 and 94.1% in Sweden. 37 In this study, 89.52% of the PZA-resistant strains harboured *pncA* mutations. The 102 mutant strains harboured 100 different mutation types (including synonymous mutations) that were scattered throughout the *pncA* gene. Substitution mutations and frame shifts (due to insertion or deletion) were detected in both the open reading frames and promoter regions of *pncA*. In this study, we detected 32 new mutations. 38–42 In addition, 89 of the 100 mutations were found in only one strain, and the remaining 11 mutations, which contained 35 strains, were shared mutations. Mutations in the promoter region were associated with PZA resistance. 43,44

| Treatment Outcome | PZA Susceptible | PZA Resistant | Chi-Square | p value |
|-------------------|-----------------|---------------|------------|---------|
|                   | Number of Patients (%) (95% CI) | Number of Patients (%) (95% CI) |            |         |
| Sputum conversion | Yes: 42 (95.45 (84.52–99.44) | No: 2 (4.54 (0.55–14.57) | 93 (93.93 (87.26–97.74) | 6.06 (2.26–12.72) | 0.71 | 1 |
| Sputum conversion time | 6 months after treatment: 3 (7.14 (1.05–19.48) | 14 (33.33 (19.56–49.55) | 20 (1.08 (0.03–5.84) | 1 (21.51 (13.65–31.23) | 1 (48.39 (37.89–58.98) | 45 (29.03 (20.08–39.36) | 10.01 | 0.018 |
|                   | 12 months after treatment: 21 (50 (34.19–65.81) | 45 (29.03 (20.08–39.36) | 27 (29.03 (20.08–39.36) | 32 (32.00 (21.00–43.00) | 3 (3.00 (1.00–5.00) | 7 (7.00 (4.00–10.00) | 0.05 | 0.82 |
|                   | 18 months after treatment: 4 (9.52 (2.65–22.62) | 24 (48.98 (37.89–58.98) | 21 (21.51 (13.65–31.23) | 32 (32.00 (21.00–43.00) | 3 (3.00 (1.00–5.00) | 7 (7.00 (4.00–10.00) | 0.05 | 0.82 |
|                   | 24 months after treatment: 3 (7.14 (1.05–19.48) | 14 (33.33 (19.56–49.55) | 20 (1.08 (0.03–5.84) | 1 (21.51 (13.65–31.23) | 1 (48.39 (37.89–58.98) | 45 (29.03 (20.08–39.36) | 10.01 | 0.018 |

Table 7 Correlation Between Treatment Outcome and Drug Susceptibility for PZA
genetically clustered. It was found that three of five strains with the promoter substitution mutation (T-12C) and five of seven strains with a substitution mutation at codon 359 were genetically in the Beijing family. Similar genetic classifications were found for substitution mutations at codon 226 (two of four isolates belonging to Beijing family), codon 203 (Beijing family), codon 398 (T family) and codon 416, and all of them were phenotypically resistant. Previous studies have suggested a correlation between \textit{pncA} mutations and gene clustering,\textsuperscript{12,45,46} but we were unable to determine gene clustering due to the small sample size and the dominant Beijing genotype.

The11 strains without \textit{pncA} mutations could involve other mechanisms of PZA resistance;\textsuperscript{11,13,15} therefore, \textit{panD} and \textit{rpsA} mutations were analysed in this study. In 2011, Shi et al reported that \textit{rpsA} could be another PZA resistance-related gene.\textsuperscript{13} However, limited data are available to explain the relationship between \textit{rpsA} mutations and PZA susceptibility; thus, the contribution of the \textit{rpsA} mutations conferring PZA resistance has been controversial until now. Alexander et al found no \textit{rpsA} mutations in PZA-resistant isolates but one \textit{rpsA} protein mutation (A364G) in 13 PZA-sensitive strains;\textsuperscript{47} Bhuju et al did not find any \textit{rpsA} mutations among either PZA-resistant isolates or PZA-susceptible isolates.\textsuperscript{34} In addition, Pang et al found no genetic mutations associated with PZA resistance in the \textit{rpsA} gene among MDR-TB patients.\textsuperscript{23} In this study, the \textit{rpsA} mutation frequency (6.7%) in MDR strains was higher than in these reports. A high synonymous mutation frequency was observed at codon212 in both PZA-resistant and PZA-susceptible strains. However, no missense or deletion/insertion mutations in \textit{rpsA} were detected in PZA-susceptible strains. Tan et al reported three nonsynonymous mutations in the \textit{rpsA} C-terminal region;\textsuperscript{48} Gu et al also identified seven of 26 mutations occurring in the C-terminal region.\textsuperscript{24} Moreover, Khan’s research found that the majority of \textit{rpsA} mutations were located in nucleotides 973–1051 of the coding region, especially nucleotides 1024–1030.\textsuperscript{49} In line with previous reports, we detected a mutation hotspot at the C-terminus of \textit{rpsA}. Moreover, five of the eight \textit{rpsA} mutations have never been described in previous studies, so further research is needed to investigate the effects of these new mutations on PZA resistance. In addition, the XDR strains in this study had a greater tendency to harbour \textit{rpsA} mutations than the MDR strains, also demonstrating that \textit{rpsA} mutations might be related to PZA resistance. While previous studies have shown that \textit{panD} is a target for PZA resistance in \textit{M. tuberculosis}, few studies have been conducted to investigate \textit{panD} mutations in clinical strains. This study showed that two (1.9%) PZA-resistant strains harboured a \textit{panD} mutation, one of which had wild-type \textit{pncA}. In summary, we identified eight PZA-resistant strains without any known mutations, indicating that additional unknown mechanisms are involved in PZA resistance and requiring further research. For PZA resistance, the combination of all three genes sequenced achieved sensitivity of 92.38% and specificity of 89.36%, consistent with other reports. Considering the insufficient reliability and inconsistency between phenotypes and the drug susceptibility test, the sequencing of all three PZA-resistant genes could evaluate the resistance of PZA more effectively.

Finally, we analysed the outcomes of 124 patients under different treatment regimes. The sputum smear/culture conversion rate was slightly higher in PZA-sensitive patients than in PZA-resistant patients (95.5% vs. 93.9%), but the difference was not statistically significant. However, subgroup analysis showed that at the end of 6 months of treatment, the sputum smear/culture conversion rate was significantly higher in PZA-sensitive MDR-TB patients than in PZA-resistant patients (71.4% vs. 1.08%), suggesting that PZA resistance prolonged the time to sputum smear/culture conversion.

This study had several limitations. First, the sample size was small, and all of the strains were derived from our region. As a result, the results might not be representative and might not apply to other regions; therefore, more samples are needed in the future. Second, we detected 32 new \textit{pncA} mutations and five new \textit{rpsA} mutations, and further research is needed to investigate their effects on PZA resistance.

In summary, this study was the first to investigate the molecular characterization of PZA resistance in MDR strains from Henan. The results showed that PZA resistance was substantially related to \textit{pncA} mutations, which were scattered and diverse. In addition, \textit{rpsA} and \textit{panD} mutations were related to PZA resistance only in MDR strains without \textit{pncA} mutations. With the resistance phenotype as the reference, molecular diagnosis with the combination of \textit{pncA}, \textit{rpsA}, and \textit{panD} achieved sensitivity of 98.1% and specificity of 92.3%. Given the high PZA resistance rate in MDR-TB patients and that PZA resistance prolonged the time to sputum smear/culture conversion, the effects of PZA should be considered carefully for MDR-TB patients in high TB burden regions. In
conclusion, the combination of \textit{pncA}, \textit{rpsA}, and \textit{panD} enabled rapid and accurate prediction of PZA resistance, helped guide the use of PZA and optimized treatment therapy for MDR-TB patients in Henan.

\textbf{Acknowledgments}

This research received no specific grants from any funding agencies in the public, commercial, or not-for-profit sectors. We thank the staff of the CDC and TB dispensaries involved in this study. We are also grateful to Guolong Zhang for his constructive comments on this study.

\textbf{Disclosure}

The authors report no conflicts of interest in this work.

\textbf{References}

1. Diacon AH, Van Baalen B, Theeuwes M. More on treatment outcomes in multidrug-resistant tuberculosis. \textit{N Engl J Med}. 2016;375(26):2609–2610.

2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. \textit{PLoS One}. 2009;4(9):e6914. doi:10.1371/journal.pone.0006914

3. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. \textit{Lancet}. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1

4. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. \textit{N Engl J Med}. 2012;366(23):2161–2170. doi:10.1056/NEJMoa1108789

5. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. \textit{Lancet}. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-2

6. Dheda K, Chang KC, Guglielmi L, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. \textit{Clin Microbiol Infect}. 2017;23(3):131–140. doi:10.1016/j.cmi.2016.10.008

7. Scorpio A, Lindholm-Levy P, Herfets L, et al. Characterization of \textit{pncA} mutations in pyrazinamide-resistant Mycobacterium tuberculosis. \textit{Antimicrob Agents Chemother}. 1997;41(3):540–543. doi:10.1128/AAC.41.3.540

8. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. \textit{Microbiol Spect}. 2014;2(4):MG2M-0023-2013. doi:10.1128/microbiolspec.MG2M-0023-2013

9. Mestdagh M, Fonteyne PA, Realini L, et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the \textit{pncA} locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. \textit{Antimicrob Agents Chemother}. 1999;43(9):2317–2319. doi:10.1128/AAC.43.9.2317

10. Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. \textit{Antimicrob Agents Chemother}. 2012;56(10):5186–5193. doi:10.1128/ AAC.00535-11

11. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in \textit{panD} encoding aspartate deoxynasylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. \textit{Emerg Microbes Infect}. 2013;2(6):e34. doi:10.1038/emi.2013.38

12. Huy NQ, Lucie C, Hoa TTT, et al. Molecular analysis of pyrazinamide resistance in \textit{Mycobacterium tuberculosis} in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. \textit{Emerg Microbes Infect}. 2017;6(10):e86. doi:10.1038/emi.2017.73

13. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. \textit{Science}. 2011;333(6049):1630–1632. doi:10.1126/science.1208813

14. Zhang Y, Chiu Chang K, Leung CC, et al. ‘Z(S)-MDR-TB’ versus ‘Z(R)-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. \textit{Emerg Microbes Infect}. 2012;1(7):e5. doi:10.1038/emi.2012.18

15. Tam KK, Leung KS, Siu GK, et al. Direct detection of pyrazinamide resistance in mycobacterium tuberculosis by use of \textit{pncA} PCR sequencing. \textit{J Clin Microbiol}. 2019;57:8. doi:10.1128/JCM.00145-19

16. Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999–2009. \textit{Clin Infect Dis}. 2013;57(8):1081–1093. doi:10.1093/cid/cit542

17. Shi J, Zheng D, Zhu Y, et al. Role of MIRU-VNTR and spoligotyping in assessing the genetic diversity of \textit{Mycobacterium tuberculosis} in Henan Province, China. \textit{BMC Infect Dis}. 2018;18(1):447. doi:10.1186/s12879-018-3351-y

18. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. \textit{J Clin Microbiol}. 1997;35(4):907–914. doi:10.1128/JCM.35.4.907-914.1997

19. Chen YY, Chang JR, Wu CD, et al. Combining molecular typing and spatial pattern analysis to identify areas of high tuberculosis transmission in a moderate-incidence county in Taiwan. \textit{Sci Rep}. 2017;7(1):5394. doi:10.1038/s41598-017-05674-6

20. Mokrousov I, Ly HM, Otten T, et al. Origin and primary dispersal of the \textit{Mycobacterium tuberculosis} Beijing genotype: clues from human phylogeography. \textit{Genome Res}. 2005;15(10):1357–1364. doi:10.1101/gr.3840605

21. Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naikoo K. Evolution of drug resistance in \textit{Mycobacterium tuberculosis}: a review on the molecular determinants of resistance and implications for personalized care. \textit{J Antimicrob Chemother}. 2018;73(5):1138–1151. doi:10.1093/jac/dkx506

22. Zhang Y, Yew WW. Mechanisms of drug resistance in \textit{Mycobacterium tuberculosis}: update 2015. \textit{Int J Tuberculosis Lung Dis}. 2015;19(11):1276–1289. doi:10.5588/ijtld.15.0389

23. Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant \textit{Mycobacterium tuberculosis} isolates from Southern China. \textit{BMC Infect Dis}. 2017;17(1):711. doi:10.1186/s12879-017-2761-6

24. Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with \textit{pncA}, \textit{rpsA}, and \textit{panD} gene mutations. \textit{Diagn Microbiol Infect Dis}. 2016;84(3):207–211. doi:10.1016/j.diagmicrobio.2015.10.017

25. Xu P, Wu J, Yang C, et al. Prevalence and transmission of pyrazinamide-resistant \textit{Mycobacterium tuberculosis} in China. \textit{Tuberculosis}. 2016;96:58–61. doi:10.1016/j.tube.2016.02.008

26. Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant \textit{Mycobacterium tuberculosis} clinical isolates in Hangzhou, China. \textit{Clin Microbiol Infect}. 2018;24(9):1016.e101–e1016.e1015. doi:10.1016/j.cmi.2017.12.012

27. Gopal P, Gruber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. \textit{Trends Pharmacol Sci}. 2019;40(12):930–940. doi:10.1016/j.tips.2019.10.005

28. Alame-Emame AK, Xu P, Pierre-Audigier C, et al. Pyrazinamide resistance in \textit{Mycobacterium tuberculosis} arises after rifampicin and fluoroquinolone resistance. \textit{Int J Tuberculosis Lung Dis}. 2015;19(6):679–684. doi:10.5588/ijtld.14.0768
29. Zignol M, Dean AS, Alilkanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. *Lancet Infect Dis*. 2016;16(10):1185–1192. doi:10.1016/S1473-3099(16)30190-6

30. Zignol M, Floyd K. Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones - authors' reply. *Lancet Infect Dis*. 2017;17(1):25. doi:10.1016/S1473-3099(16)30538-2

31. Budzik JM, Jarlsberg LG, Higashi J, et al. Pyrazinamide resistance. *Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California*. *PLoS One*. 2014;9(4):e95645. doi:10.1371/journal.pone.0095645

32. Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. *Nat Commun*. 2014;5:5792. doi:10.1038/ncomms6792

33. Raju S, Ye CJ. How mutations express themselves in blood-cell production. *Nature*. 2019;571(7765):329–330. doi:10.1038/d41586-019-02028-2

34. Bhuj S, Fonseca Lds S, Marsico AG, et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. *Infect Genetics Evol*. 2013;19:1–6. doi:10.1016/j.meegid.2013.06.008

35. Dowstah F, Khosravi AD, Farnia P. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. *Microb Drug Resist*. 2009;15(4):251–256. doi:10.1089/mdr.2009.0066

36. Jonnalag J, Prammannan T, Leechawengwongs M, Chairparset A. Surveillance of pyrazinamide susceptibility among multidrug-resistant *Mycobacterium tuberculosis* isolates from Siriraj Hospital, Thailand. *BMC Microbiol*. 2010;10:223. doi:10.1186/1471-2180-10-223

37. Jureen P, Wengren J, Toro JC, Hoffner S. Pyrazinamide resistance and pncA gene mutations in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2008;52(5):1852–1854. doi:10.1128/AAC.00110-08

38. Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. *PLoS One*. 2015;10(7):e0133869. doi:10.1371/journal.pone.0133869

39. Li D, Hu Y, Wengren J, et al. Multicenter study of the emergence and genetic characteristics of pyrazinamide-resistant tuberculosis in China. *Antimicrob Agents Chemother*. 2016;60(9):5159–5166. doi:10.1128/AAC.02687-15

40. Zheng X, Ning Z, Drobniewski F, et al. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis. *Int J Antimicrob Agents*. 2017;49(2):183–188. doi:10.1016/j.ijantimicag.2016.10.012

41. Spinato J, Boivin E, Belanger-Tradelle E, Fauchon H, Tremblay C, Soualhine H. Genotypic characterization of drug resistant *Mycobacterium tuberculosis* in Quebec, 2002-2012. *BMC Microbiol*. 2016;16(1):164. doi:10.1186/s12866-016-0786-4

42. Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of *Mycobacterium tuberculosis* from Khyber Pakhtunkhwa, Pakistan. *BMC Infect Dis*. 2019;19(1):116. doi:10.1186/s12879-019-3764-2

43. Sheen P, Lozano K, Gilman RH, et al. pncA gene expression and prediction factors on pyrazinamide resistance in *Mycobacterium tuberculosis*. *Tuberculosis*. 2013;93(5):515–522. doi:10.1016/j.tube.2013.03.005

44. Filipenko ML, Dymova MA, Cherednichenko AG, Khrapov EA, Mishukova OV, Schwartz YS. Detection of Mutations in Mycobacterium tuberculosis pncA gene by modified high-resolution melting curve analysis of PCR products. *Bull Exp Biol Med*. 2019;168(2):264–269. doi:10.1007/s10517-019-04688-6

45. Rodrigues Ve D, Telles MA, Ribeiro MO, Cafrune PI, Rossetti ML, Zaha A. Characterization of pncA mutations in pyrazinamide-resistant *Mycobacterium tuberculosis* in Brazil. *Antimicrob Agents Chemother*. 2005;49(1):444-446. doi:10.1128/ AAC.49.1.444-446.2005

46. Rahman A, Ferdous SS, Ahmed S, et al. Pyrazinamide susceptibility and pncA mutation profiles of *Mycobacterium tuberculosis* among multidrug-resistant tuberculosis patients in Bangladesh. *Antimicrob Agents Chemother*. 2017;61:9. doi:10.1128/AAC.00511-17

47. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jameson FB. Gene sequencing for routine verification of pyrazinamide resistance in *Mycobacterium tuberculosis*: a role for pncA but not rpsA. *J Clin Microbiol*. 2012;50(11):3726–3728. doi:10.1128/JCM.00620-12

48. Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in *Mycobacterium tuberculosis* isolates from southern China. *J Clin Microbiol*. 2014;52(1):291–297. doi:10.1128/JCM.01903-13

49. Khan MT, Malik SI, Bhatti AI, et al. Pyrazinamide-resistant *mycobacterium tuberculosis* isolates from Khyber Pakhtunkhwa and rpsA mutations. *J Biol Regul Homeost Agents*. 2018;32(3):705–709.